medigraphic.com

2020, Number 3

<< Back Next >>

Cuba y Salud 2020; 15 (3)

Amyotrophic Lateral Sclerosis, efficacy of its multidisciplinary management Institute of Neurology and Neurosurgery. 2005-2017

Lara FGE, Scull TM, Zaldivar VT, Arias MA, Gutierrez GJ

Language: Spanish
References: 26
Page: 12-18
PDF size: 766.72 Kb.


ABSTRACT

Objective: to evaluate the effectiveness of the multidisciplinary care process for patients with Amyotrophic Lateral Sclerosis treated at the Institute of Neurology and Neurosurgery in the period 2005- 2017.
Method: an evaluation of the effectiveness of the multidisciplinary care process was carried out for patients with Amyotrophic Lateral Sclerosis treated at the Institute of Neurology and Neurosurgery, through an intervention from 2012 on quality of care and health records; it was divided into two stages. In the period 2005-2011, 72 patients were included in the study and in 2012-2017 (75). Statistical processing was carried out through the comparison of the means of two non-parametric samples, the Mann Whitney U test, and the comparison of proportions by the Z proportions comparison test, with a reliability of 95% and p <0.05.
Results: during the period 2012-2017 a decrease in diagnostic latency was obtained for bulbar form in 3.24 months; 5.4 more months of survival and there was no place of death without specifying and inclusion of Amyotrophic Lateral Sclerosis as a cause of death in 96% of the death certificates, all statistically significant.
Conclusions: the multidisciplinary care process for patients with Amyotrophic Lateral Sclerosis treated at the Institute of Neurology and Neurosurgery during the period 2005-2017 was evaluated as effective.


REFERENCES

  1. Brown RH,Al-Chalabi A.Amyotrophic Lateral Sclerosis.N.Engl.J.Med.2017;377: 162-72.

  2. Chiò A,Logroscino G,Traynor BJ,Collins J,Simeone JC,Goldstein LA, White LA.Global Epidemiology of Amyotrophic Lateral Sclerosis:a Systematic Review of the Published Literature.Neuroepidemiology 41(2013):118-30.

  3. Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population. A population-based mortality study. Neurology.[Internet]2009;[consultado 3 de marzo de 2019]72:1640-5. Disponible en: n.neurology.org/ content/72/19/1640.short

  4. Ryan M, Zaldívar Vaillant T, McLaughlin RL, Doherty MA, Rooney J, Heverin M, Gutiérrez J, Lara-Fernández GE, Pita Rodríguez M, Hackembruch J, Perna A, Vazquez MC, Musio M, Ketzoian CN, Logroscino G, Hardiman O.Comparison of the clinical and genetic features of amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic-based populations. JNeurolNeurosurgPsychiatry. 2019 Mar 7.pii: jnnp-2018-319838. doi:10.1136/jnnp-2018-319838

  5. Geevasinga N, Menon P, Scherman DB, et al. Diagnostic criteria in amyotrophic lateral sclerosis:a multicenter prospective study.Neurology [Internet].2016;[Citado el 5 de Nov. de 2019] Aug16;87(7):684-90. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27440148

  6. Boekestein Werner A, et al.Sensitivity and specificity of the ‘Awaji’ electrodiagnostic criteria for amyotrophic lateral sclerosis:Retrospective comparison of the Awaji and revised El Escorial criteria for ALS. Amyotrophic Lateral Sclerosis[Internet]2011;[Citado el 10 de Nov. de 2019] (6):497-501. Disponible en: https://researchgate.net/publication/44661936 Sensitivity_and_specificity_of_the_’Awaji’_electrodiagnostic_ criteria_for_amyotrophic_lateral_sclerosis_Retrospective_comparison_of_the_Awaji_and_revised_El_Escorial_criteria_for_ALS

  7. Rooney J, Byrne S,Heverin M.A multidisciplinary clinic approach improves survival in ALS:a comparative study of ALS in Ireland and Northern Ireland.J NeurolNeurosurgPsychiatry[Internet].2015; [Citado el 5 /Nov/2019]86:496-01. Disponible en: https://www.ncbi.nlm.nih.gov/ pubmed/25550416

  8. Hogden A, Foley G, Henderson RD, James N, Aoun SM. Amyotrophic lateral sclerosis:improving care with a multidisciplinary approach. Journalof MultidisciplinaryHealthcare[Internet].2017;[Citado el 12/Oct/2019]10:205-15. Disponible en : https://www.researchgate.net/ publication/317109729_Amyotrophic_lateral_sclerosis_Improving_care_with_a_multidisciplinary_approach

  9. Rechtman L.ALS Incidence Varies by Race and Ethnicity. Neurology Reviews. 2014 September;22(9):18

  10. Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States:A summary report and call to action. Annals of Neurology[Internet]. 2017; [Citado el 15/Oct/2019]81(4):479-84. Disponible en: https://ncbi.nlm.nih.gov/pubmed/28198092

  11. Zapata-Zapata CH, Franco-Dager E, Solano-Atehortúa JM, Ahunca-Velásquez LF. Esclerosis lateral amiotrófica: actualización. Iatreia. 2016Abr- Jun;29(2):194-205. DOI10.17533/udea.iatreia.v29n2a08.

  12. Hardiman O, Al Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W,et al. Amyotrophic lateral sclerosis.NatRevDisPrimers.2017;3:17071. doi: 10.1038/nrdp.2017.71, 28980624

  13. Harrison D, Mehta P, Ivan Es MA, Stommel E, Drory VE, Nefussy B, et at. “ALS reversals”: Demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degener[Internet].2018;[Citado el 5/Nov/2019]19:495-499. Disponible en: https://ncbi.nlm.nih.gov/pubmed/29607695

  14. Velázquez Pérez L, Gilberto Sánchez C, Nieves Santos F, Almaguer MederosLE, Escalona Batallan Ked al. Molecular epidemiology of spinocerebellar ataxias in Cuba: Insights into SCA2 founder effect in Holguin. Neuroscience Letters; [Internet]2009.[consultado 3 /marzo/ 2019]454: 157–160

  15. Alcalde Muñoz S, Pejenaute Labari E. ¿Qué sabemos de la esclerosis lateral amiotrófica?.FMC en Atención Primaria.2017;24(4): 180-8.

  16. Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, Chinea A. A comprehensive review of amyotrophic lateral sclerosis.Surg NeurolInt[Internet]2015;[Citado el 7 de Sept. de 2019]6:171. Disponible en:https://ncbi.nlm.nih.gov/pubmed/26629397

  17. Marin B,Couratier P,Arcuti S,Copetti M,Fontana A,Nicol M,Raymondeau M, Logroscino G,Preux PM. Stratification of ALS patients’ survival: a population-based study. JNeurol.2016;263:100-111.10.1007/s00415-015-7940-z. 26518423 Disponible en:https://elsevier.com/locate/neulet

  18. Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: An update for 2018. MayoClin.Proc.2018;93:1617-1628.DOi:10.1016/j. mayocp.2018.04.007

  19. Bucheli ME, Campos M, Bermudes DB, Chuquimarca JP, Sambache K, Niato JF, Villalba P, Montalvo J, Andino A, Calero C, Guerrero P. Esclerosis Lateral Amiotrófica: Revisión de Evidencia Médica para Tratamiento.Rev.Ecuat.Neurol.Vol.22;No1-3, 2013.

  20. Provinciali L, Carlini G, Tarquini D,Defanti CA,Veronese S,Pucci E. Need for palliative care for neurological diseases. Neurological Sciences [Internet].2016; [Citado el 12 /oct/2019]37(10):1581-1587. Disponible en:http://europepmc.org/article/med/27299428

  21. Serra Ruiz M, Serra Valdés MA. Sobrevida en pacientes con Esclerosis lateral amiotrofica. Revista Habanera de Ciencias Médicas [revista en Internet].2019[citado 2020 mayo 2];18(4): aprox.11ap. Disponible en: https://revhabanera.sld.cu/index.php/rhab/article/view/2867

  22. van Groenestijn AC, Kruitwagen-van Reenen ET, Visser-Meily JM, van den Berg LH, Schröder CD. Associations between psychological factors and health-related quality of life and global quality of life in patients with ALS: a systematic review. Health Qual Life Outcomes [Internet].2016;[Citado el 5 de Nov. de 2019]14:107. Disponible en: https://ncbi.nlm.nih.gov/pmc/articles/PMC4955215/

  23. Adriano Chiò, Corrado Magnani, Enrico Oddenino, Gianpiero Tolardo and David Schiffer. Accuracy of Death Certificate Diagnosis of Amyotrophic Lateral Sclerosis. Journal of EpidemiologyandCommunityHealth.1992;46(5): 517-18

  24. Ong Ml, Tan PK, Holbrook JD. Predicting functional decline and survival in Amyotrophic Lateral sclerosis.PLos ONE 2017;12(4):e o174925. Disponible en:https://doi.org/10.1371/journal

  25. Pupillo E, Messina P, Logroscino G,et al. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol2014;75(2):287Y297. doi:10.1002/ ana.24096

  26. Elodie J, O’Connor and Marita P. McCabe. Predictors of quality of life in carers for people with a progressive neurological illness: a longitudinal study. Quality of Life Research.2011; 20(5):708-11. (June 2011), pp. 703-711. Disponible en: https://www.jstor.org/stable/41488125




2020     |     www.medigraphic.com